CRC has an immunosuppressive TME which prevents the development of an efficient response to ICB therapies. There is thus an urgent need to identify the approaches reprogram this suppressive TME in an effort to boost immunotherapy efficacy. In the current research, we utilized CRISPR KO screens to discover genes that https://apigenin66543.shotblogs.com/5-easy-facts-about-l-buthionine-s-r-sulfoximine-described-42717715